Literature DB >> 8666110

Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension.

N F Voelkel1, R M Tuder.   

Abstract

Chronic pulmonary hypertension leads to structural alterations of the lung vessels. The pathophysiology of this remodelling process is still poorly understood. Furthermore, the structural damage of the lung vessels limits the clinical success of vasodilator treatment. Given a genetic susceptibility, shear stress and inflammation are the principal pathogenetic factors involved in lung vessel remodelling. In this overview, we compared the lung vascular histology of patients with unexplained pulmonary hypertension, scleroderma, or acquired immune deficiency syndrome (AIDS)-associated pulmonary hypertension. We demonstrate the presence of inflammatory cells (T- and B-lymphocytes and macrophages) in plexiform lesions and discuss the potential role of growth factors (platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-beta) and vascular endothelial growth factor (VEGF) in pulmonary hypertensive remodelling. Ultimately, we need to develop an in-depth understanding of the key mechanisms of gene expression and signalling pathways, which transduce signals generated from increased chronic shear stress (or from chronic hypoxia) and lead to vascular injury and repair.

Entities:  

Mesh:

Year:  1995        PMID: 8666110     DOI: 10.1183/09031936.95.08122129

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  34 in total

Review 1.  Primary pulmonary hypertension: the pressure rises for a gene.

Authors:  J R Thomson; R C Trembath
Journal:  J Clin Pathol       Date:  2000-12       Impact factor: 3.411

Review 2.  An update on the evaluation and management of pulmonary hypertension in scleroderma.

Authors:  John G Coghlan; Benjamin Schreiber; Benjamin Schrieber
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

3.  Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis?

Authors:  S I Said; S A Hamidi; L Gonzalez Bosc
Journal:  Eur Respir J       Date:  2010-04       Impact factor: 16.671

Review 4.  [Pulmonary diseases and heart function].

Authors:  K Rasche; M Orth; A Kutscha; H W Duchna
Journal:  Internist (Berl)       Date:  2007-03       Impact factor: 0.743

5.  Galectin-3: A Harbinger of Reactive Oxygen Species, Fibrosis, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  David J R Fulton; Xueyi Li; Zsuzsanna Bordan; Yusi Wang; Keyvan Mahboubi; R Daniel Rudic; Stephen Haigh; Feng Chen; Scott A Barman
Journal:  Antioxid Redox Signal       Date:  2019-03-29       Impact factor: 8.401

6.  Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.

Authors:  S D Lee; K R Shroyer; N E Markham; C D Cool; N F Voelkel; R M Tuder
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

7.  Network analysis of temporal effects of intermittent and sustained hypoxia on rat lungs.

Authors:  Wei Wu; Nilesh B Dave; Guoying Yu; Patrick J Strollo; Elizabeta Kovkarova-Naumovski; Stefan W Ryter; Stephen R Reeves; Ehab Dayyat; Yang Wang; Augustine M K Choi; David Gozal; Naftali Kaminski
Journal:  Physiol Genomics       Date:  2008-09-30       Impact factor: 3.107

8.  Leptin deficiency recapitulates the histological features of pulmonary arterial hypertension in mice.

Authors:  Metin Aytekin; Adriano R Tonelli; Carol F Farver; Ariel E Feldstein; Raed A Dweik
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

9.  CD4+ T cells and IFN-γ are required for the development of Pneumocystis-associated pulmonary hypertension.

Authors:  Steve D Swain; Dan W Siemsen; Rebecca R Pullen; Soo Han
Journal:  Am J Pathol       Date:  2013-12-21       Impact factor: 4.307

10.  Adenoviral transfer of vasoactive intestinal peptide (VIP) gene inhibits rat aortic and pulmonary artery smooth muscle cell proliferation.

Authors:  Rose-Claire St Hilaire; Philip J Kadowitz; James R Jeter
Journal:  Peptides       Date:  2009-08-19       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.